| __timestamp | ADMA Biologics, Inc. | Apellis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 2908166 |
| Thursday, January 1, 2015 | 6745968 | 6356782 |
| Friday, January 1, 2016 | 8494742 | 4303743 |
| Sunday, January 1, 2017 | 18092835 | 10463151 |
| Monday, January 1, 2018 | 22502922 | 22639184 |
| Tuesday, January 1, 2019 | 25910757 | 67046483 |
| Wednesday, January 1, 2020 | 35050817 | 139401000 |
| Friday, January 1, 2021 | 42896889 | 176771000 |
| Saturday, January 1, 2022 | 52458024 | 277163000 |
| Sunday, January 1, 2023 | 59020000 | 500815000 |
Unleashing insights
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. Over the past decade, ADMA Biologics, Inc. and Apellis Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics saw a steady increase in SG&A expenses, growing by over 1,100%, reflecting their strategic investments in operational expansion. Meanwhile, Apellis Pharmaceuticals experienced a staggering rise of nearly 17,000% in the same period, indicating aggressive scaling and market penetration efforts. By 2023, Apellis's SG&A expenses were approximately 8.5 times higher than ADMA's, highlighting their divergent financial strategies. This comparison offers valuable insights into how biotech companies manage costs while navigating the complexities of the industry.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs ADMA Biologics, Inc.
Regeneron Pharmaceuticals, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Pharming Group N.V. vs Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Apellis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and Viking Therapeutics, Inc.
ADMA Biologics, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
Comparing SG&A Expenses: ADMA Biologics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Perrigo Company plc
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared